Expert Review of Pharmacoeconomics & Outcomes Research

Papers
(The H4-Index of Expert Review of Pharmacoeconomics & Outcomes Research is 14. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-03-01 to 2024-03-01.)
ArticleCitations
Burden and socioeconomics of asthma, allergic rhinitis, atopic dermatitis and food allergy144
Potential approaches for the pricing of cancer medicines across Europe to enhance the sustainability of healthcare systems and the implications43
An overview of the time trade-off method: concept, foundation, and the evaluation of distorting factors in putting a value on health40
Real-world reduction in healthcare resource utilization following treatment of opioid use disorder with reSET-O, a novel prescription digital therapeutic34
Organizational measures aiming to combat COVID-19 in the Russian Federation: the first experience32
Distinguishing features in the assessment of mHealth apps30
Burden of disease and costs associated with type 2 diabetes in emerging and established markets: systematic review analyses27
Cost-effectiveness analyses of breast cancer medications use in developing countries: a systematic review27
Tools to assess the quality of life in patients with Parkinson’s disease: a systematic review26
First-line atezolizumab plus chemotherapy in advanced non-squamous non-small cell lung cancer: a cost-effectiveness analysis from China24
Will the Markov model and partitioned survival model lead to different results? A review of recent economic evidence of cancer treatments20
Health-related quality of life in patients with chronic kidney disease20
Evaluation instruments for executive functions in children and adolescents: a systematic review17
Cost-effectiveness of adding durvalumab to first-line chemotherapy for extensive-stage small-cell lung cancer in China14
Prevalence of chronic respiratory morbidity, length of stay, inpatient readmissions, and costs among extremely preterm infants with bronchopulmonary dysplasia14
Valuing health outcomes: developing better defaults based on health opportunity costs14
The transferability of health technology assessment: the European perspective with focus on central and Eastern European countries14
0.036796092987061